Thus, these findings indicated that in PDA fraxetin hinders hypoxia-induced angiogenesis by decreasing the expression levels of HIF-1α and VEGFA, controlling glucose uptake and metabolism by reducing GLUT1 expression, and inhibiting EMT by blocking the Slug-E-cadherin axis. The gene discussed is VEGFA; the disease is Patent ductus arteriosus.